Amgen Inc

Amgen’s Q4 earnings beat expectations, driving the stock to a 52‑week high and a $350 target as institutional buying surges.

Amgen’s $1.4 billion oncology acquisition spree signals a bold push toward cancer therapies, promising pipeline growth amid a biotech boom and investor optimism.

Amgen’s 2025 earnings and pipeline fuel a bullish outlook, with oncology and chronic disease growth, analyst upgrades, and strong R&D discipline driving investor confidence.

Amgen’s biotech edge: how its robust R&D, precision‑medicine pipeline and scalable manufacturing position it to lead the booming recombinant antibody and protein market.

Amgen’s new U.S. drug‑price plan and the launch of denosumab biosimilars reveal how the company balances cost cuts with innovation—boosting its market edge and shareholder value.

Amgen’s Repatha cuts first heart attack risk by 36% in VESALIUS‑CV, boosting investor confidence and market value.

Amgen Inc. experienced significant developments in the week of October 23, 2025, including a shareholder rights inquiry, regulatory approval for its respiratory therapy Tezspire, and recognition in the thrombocytopenia market, with its share price r…

Amgen Inc. has exceeded expectations with a 9% revenue increase, prompting a revised 2025 revenue forecast and a $500 million share repurchase program.

Amgen Inc. reports a 9% increase in total revenues to $9.2 billion in Q2 2025, driven by its commitment to delivering innovative medicines and biosimilars.

Amgen Inc. has announced promising results from its Phase 2 obesity study of MariTide, a potential groundbreaking treatment for obesity, particularly in patients with type 2 diabetes.